News | Nuclear Imaging | April 20, 2016

Top U.K. Cancer Center Chooses Mirada Medical Technology

Agreement will bring proton therapy, MR-guided linear accelerators and PET/MR technology to U.K. hospital

Mirada Medical, The Christie Hospital, England, PET-MRI, radiation therapy

April 20, 2016 — Mirada Medical announced a new agreement to work with the clinicians and physicists at The Christie Hospital in Manchester, England, a world-renowned centre for complete cancer care. The Christie is the only U.K. hospital that will be treating cancer patients with proton therapy and magnetic resonance imaging (MRI)-guided linear accelerators (LINAC), whilst benefiting from the latest advancements in diagnostics with positron emission tomography (PET)/MRI.

With Mirada specializing in software to enable collaboration between departments and treatment methods, this is a natural relationship that will support fundamental changes in treatment protocols, reducing time to treatment whilst improving clinical confidence and efficacy.

“We have chosen Mirada as strategic partner to develop multimodality imaging solutions because of the quality of their software, allowing rapid translation of novel techniques into our clinic while also providing the possibility to efficiently integrate workflows for the different treatment techniques that are available at our site,” said Prof. Marcel Van Herk, chair in radiotherapy physics at the University of Manchester and The Christie NHS Foundation Trust.

For more information: www.mirada-medical.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...